Unique Applications of Novel Antifungal Drug Combinations

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)

Volume 14, 2 Issues, 2016

Download PDF Flyer

Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Unique Applications of Novel Antifungal Drug Combinations

Anti-Infective Agents, 6(1): 3-15.

Author(s): Chiatogu Onyewu and Joseph Heitman.

Affiliation: Department of Molecular Genetic and Microbiology, 322 Carl Building, Box 3546, Research Drive,Duke University Medical Center, Durham, NC 27710, USA.


Candida albicans is a commensal fungal organism that can over-proliferate and cause disease in the appropriate host setting. C. albicans can cause irritating superficial skin and mucocutaneous infections such as diaper rash and vaginal yeast infections, respectively. In immunocompromised hosts, these infections can progress to disseminated disease in which the organism enters the blood and colonizes multiple organs. Consequently, Candida infections result in a considerable amount of morbidity and mortality every year. Most modern-day antifungal drugs block ergosterol biosynthesis. Several of these agents are fungistatic and do not kill the fungal cell, thus facilitating the emergence of drugresistant species, which further complicate therapy. Alternatively, some of the most effective antifungal drugs are too toxic for continuous use or can only be administered intravenously. The ideal antifungal drug would be non-toxic, fungicidal, and amenable to self-administration. Previous studies have demonstrated that specific commercially available drugs from two unrelated drug classes (calcineurin inhibitors and ergosterol biosynthesis inhibitors) act synergistically to kill Candida by targeting distinct molecular pathways in the organism. Calcineurin inhibitors are immunosuppressive agents, so systemic administration of these drugs would be counter-intuitive for treatment of already immunocompromised individuals. However, this drug combination can be applied to topical antifungal therapies for a variety of cutaneous and mucocutaneous fungal infections that afflict a diverse population, including immunocompromised patients.


azoles, Candida cell cultures, Echinocandins, calcineurin inhibitors, Candida infection.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 1
First Page: 3
Last Page: 15
Page Count: 13
DOI: 10.2174/187152107779314142
Superbugs USA

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science